Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial-Reference-Cited by-同舟云学术

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial

Published:2023-11 Issue: Volume:65 Page:102258
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Savarirayan Ravi^ORCID,Hoernschemeyer Daniel G.,Ljungberg Merete,Zarate Yuri A.,Bacino Carlos A.,Bober Michael B.,Legare Janet M.,Högler Wolfgang,Quattrin Teresa,Abuzzahab M. Jennifer,Hofman Paul L.,White Klane K.,Ma Nina S.,Schnabel Dirk,Sousa Sérgio B.,Mao Meng,Smith Alden,Chakraborty Mukta,Giwa Adebola,Winding Bent,Volck Birgitte,Shu Aimee D.,McDonnell Ciara^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia;Savarirayan;Nat Rev Endocrinol,2022

2. Achondroplasia;Horton;Lancet,2007

3. Achondroplasia;Baujat;Best Pract Res Clin Rheumatol,2008

4. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history;Hoover-Fong;Bone,2021

5. Achondroplasia: a comprehensive clinical review;Pauli;Orphanet J Rare Dis,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-type natriuretic peptide (CNP): The cardiovascular system and beyond;Pharmacology & Therapeutics;2024-10

2. Progress in managing children with achondroplasia;Expert Review of Endocrinology & Metabolism;2024-08-12

3. New treatments for children with achondroplasia;The Lancet Child & Adolescent Health;2024-04

4. Promising horizons in achondroplasia along with the development of new drugs;Endocrine Journal;2024